A comparison of the β1‐selectivity of three β1‐selective β‐blockers

@article{Nuttall2003ACO,
  title={A comparison of the $\beta$1‐selectivity of three $\beta$1‐selective $\beta$‐blockers},
  author={Sarah L Nuttall and Helen Routledge and Martin J. Kendall},
  journal={Journal of Clinical Pharmacy and Therapeutics},
  year={2003},
  volume={28}
}
Objective: To determine the relative β1‐selectivity of three β‐blockers (nebivolol, bisoprolol and atenolol), administered orally at normal therapeutic doses, by assessing their impact on the β2‐mediated, haemodynamic and biochemical responses to a terbutaline infusion, which decreases serum potassium and increases serum glucose and insulin. 
Nebivolol: Pharmacologic Profile of an Ultraselective, Vasodilatory β1‐Blocker
  • L. Prisant
  • Chemistry, Medicine
  • Journal of clinical pharmacology
  • 2008
TLDR
Nebivolol has a unique hemodynamic profile of reduced systemic vascular resistance and increased left ventricular function, attributed to its vasodilating action and contrast with the hemodynamic effects of conventional β‐blockers. Expand
Effects of nebivolol versus other antihypertensive drugs on the endothelial dysfunction in patients with essential hypertension
TLDR
Meta-analysis and descriptive analysis indicated that nebivolol did not have a better endothelium-protective effect than other classes of antihypertensive drugs including olmesartan and perindopril, and Nebvolol is not a unique endothelial function-Protective agent distinguished from other β-blockers or otherclasses of anti Hypertensivedrugs. Expand
Therapeutic Properties of Highly Selective β-blockers With or Without Additional Vasodilator Properties: Focus on Bisoprolol and Nebivolol in Patients With Cardiovascular Disease
TLDR
Although head-to-head trials are largely lacking, there is no clear indication from published studies of an additional effect of nebivolol on clinical outcomes in patients with HFrEF or the magnitude of reductions of BP in Patients with hypertension. Expand
Effects of nebivolol versus bisoprolol on endothelial function in hypertensive patients.
TLDR
Nebivolol treatment of untreated hypertensive patients led to a significant improvement in endothelial function compared with bisoprolol treatment, despite the similar effect on BP with either therapeutic agent. Expand
β‐Blocker Use in Heart Failure Patients with Airways Disease
TLDR
The single center experience of cautiously treating patients who have concomitant chronic heart failure with β‐Blockers is reported, with good results in patients with reversible airways disease. Expand
Pharmacological intervention in hypertension using beta‐blockers: Real‐world evidence for long‐term effectiveness
TLDR
B bisoprolol showed sustained benefit on survival, evident from 2 years after treatment initiation versus other &bgr;‐blockers, and from 5 years versus drugs other than &b gr;‐ blockers, providing long‐term evidence supporting the use of bisoproleol in patients with hypertension in primary care. Expand
Pulmonary effects of nebivolol.
TLDR
Nebivolol is a third-generation β-adrenergic receptor antagonist with high β1-selective adrenergic receptor antagonism and vasodilating properties that induces a substantial decrease of arterial pressure in hypertensive subjects while preserving their left ventricular function. Expand
Betablocker der 3. Generation: Stand der Forschung zu den Betablockern mit vasodilatierenden Zusatzeigenschaften
TLDR
Third generation, vasodilating beta-blocker with a high β1-adrenoceptor selectivity acts as an agonist at the β3 adrenoceptor as well as the estrogen receptor thereby releasing nitric oxide in blood vessels via eNOS. Expand
Tolerability of Nebivolol in Head-To-Head Clinical Trials Versus Other Cardioselective β-Blockers in the Treatment of Hypertension
TLDR
A meta-analysis revealed that the tolerability of nebivolol is superior to that of atenolol, metoprolol and bisoprool, and confirmed that nebivorol is at least as effective as these CSBs in the treatment of mild-to-moderate hypertension. Expand
Beta-blockers in the management of cardiovascular diseases
TLDR
The objective of this article is to discuss some of the clinically relevant evidenced-based research and clinical trials outcomes of commonly used β-blockers. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 38 REFERENCES
Metabolic effects of β2‐agonists
TLDR
The subject of hypokalemia, the mechanism for its production by β2‐agonists and its relevance to cardiac arrhythmias are considered in detail and the fall in plasma magnesium and the possible role of β 2‐agonists in the production of lactic acidosis are discussed. Expand
Is Metoprolol CR/ZOK More Selective Than Conventional Metoprolol and Atenolol?
An alternative, simple method to assess beta1‐selectivity is to establish the impact of the beta blocker on beta2‐stimulated increases in plasma glucose and decreases in plasma potassium during anExpand
COMPARISON OF THE EFFECTS OF (—)‐ISOPRENALINE, ORCIPRENALINE TERBUTALINE, AND ME506 ON HEART RATE, SOLEUS MUSCLE CONTRACTILITY AND PULMONARY RESISTANCE OF ANAESTHETIZED CATS
  • E. Malta, C. Raper
  • Chemistry, Medicine
  • Clinical and experimental pharmacology & physiology
  • 1976
1. Three resorcinol derivatives with N‐isopropyl (orciprenaline), N‐t‐butyl (terbutaline) and N‐p‐hydroxypheny‐t‐butyl (Me506) amine substituents have been compared with (—)‐isoprenaline for theirExpand
Are Selective Beta-Adrenoceptor Blocking Drugs an Advantage?
  • M. Kendall
  • Medicine
  • Journal of the Royal College of Physicians of London
  • 1981
TLDR
Beta-adrenoceptor blocking drugs (beta-blockers) are widely used in the treatment of hypertension, angina Pectoris and a variety of other disorders and they also differ in terms of cost, duration of effect and route of elimination. Expand
Metabolic effects of beta 2-agonists.
TLDR
The subject of hypokalaemia, the mechanism for its production by beta 2-agonists and its relevance to cardiac arrhythmias are considered in detail and the fall in plasma magnesium and the possible role of beta 1-agonists in the production of lactic acidosis are discussed. Expand
CARDIOVASCULAR AND METABOLIC EFFECTS OF TERBUTALINE
TLDR
The data suggests that the terbutaline infusion may be a useful tool for the investigator and quantitate some of the side effects which may result from the intravenous administration of a therapeutic dose of terbutalin given to asthmatics or to pregnant women to reduce uterine activity and delay childbirth. Expand
A dose-response trial of nebivolol in essential hypertension
TLDR
The combination of properties of nebivolol renders it an attractive addition to the antihypertensive repertoire and was shown to be effective given once daily, without appreciable differences between peak and trough drug levels. Expand
Modulation of Isoprenaline-Induced Metabolic and Cardiovascular Responses in Dogs by Nebivolol, Atenolol and Propranolol
TLDR
The ability of the new antihypertensive agent, d/-nebivolol, to antagonise isoprenaline (isoproterenol)-stimulated {31and {32adrenergic cardiovascular and metabolic responses in anaesthetised dogs} is evaluated. Expand
A double-blind comparison of bisoprolol and atenolol in patients with essential hypertension.
TLDR
Despite theoretical and circumstantial evidence to suggest superiority of bisoprolol over atenolol, no significant difference between the two was found except for greater heart rate reduction with bisoprole, and patient acceptability of the drugs as assessed by visual analogue scale. Expand
Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective beta 1-adrenergic antagonist.
TLDR
N is a potent and selective beta 1-adrenergic blocking agent with an interesting hemodynamic profile in hypertensive subjects and SHR, where a single dose lowers arterial blood pressure for substantial periods of time. Expand
...
1
2
3
4
...